INN : Ulenistamab
First-in-Class monoclonal antibody
PBP1510 specifically binds to PAUF and exerts anti-metastasis and immune modulation effects.


Pancreatic cancer generally expresses high level of PAUF (pancreatic adenocarcinoma upregulated factor), a protein that drives cancer cells to spread through blood flow and to escape immune recognition. PBP1510 specifically binds to PAUF and exerts anti-metastasis and immune modulation effects.

Mechanism of Action

PAUF causes vascular leakage through binding to CXCR4 receptor on cancer cells, allowing cancer cells to escape blood vessels.
This is how metastasis begins.

PAUF acts as an immune modulator: (1) PAUF binds to TLR4 receptor on monocyte and induces M2 macrophage polarization.
(2) PAUF binds to TLR4 receptor on MDSCs (myeloid-derived suppressor cells) and activates MDSCs. Both M2 and MDSC suppress anti-tumor functions
of cytotoxic T cells, leading to immune evasion of cancer cell.


[1] PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF‐κB Signalling Pathway. Oncotarget (2022).

[2] PAUF enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. Oncotarget (2016).

[3] A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. Biochem Biophys Res Commun (2014).

[4] PAUF, a novel endothelial activator, promotes angiogenesis and vascular permeability. Oncogene (2013).

[5] PAUF promotes metastasis by regulating TLR/CXCR4 activation. Oncogene (2011).

[6] PAUF, a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. Cancer Sci  (2009).

Phase of Clinical Research

Pipeline :  PBP1510

INN :  Ulenistamab

Categogy :  mAb (monoclonal antibody)

Indication :  Pancreatic cancer, Ovarian cancer

Development Stage

  • Phase 1/2a Clinical Trial in Europe and U.S. 50% 50%

Phase 1/2a
FDA Fast Track designated  (2023)
Orphan Drug Designation by EMA, FDA & Korea

Prestige Biopharma Group is participating in the <CancerX> program through its novel antibody therapy PBP1510 for pancreatic cancer and PAUF-detection pancreatic cancer diagnostic technology. This program brings together various private companies worldwide to collaboratively develop innovative treatments for challenging cancer types such as pancreatic cancer. With its involvement in <CancerX>, Prestige Biopharma Group is advancing the path of <Innovation for Life>.

CancerX Website: https://cancerx.health/

CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.